次新股異動 | 鳳祥股份升近30%創上市新高,重返發行價上方
uSMART友信智投8月17日消息,週一港股午後,次新股鳳祥股份升幅擴大,截至13:36分,鳳祥股份升28.24%,報4.36港元。
鳳祥股份於7月16日登陸港交所,發行價為3.33港元,首日收升0.9%,第二日收平,第三天即破發。
今日早間發佈的《友智內參》指出,從目前了解到的情況看,很多機構比較青睞的板塊集中在農業和券商。農業板塊是因為近期糧食問題因為高層而被關注,而港股的農業板塊是生僻板塊,所以目前估值比較便宜,比如中化化肥(297)以及鳳祥集團(9977),在細分領域都是龍頭地位,又有安全邊際,業績一旦發佈,就是很好的機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.